NEW TAIPEI CITY, Taiwan, Jan. 30, 2026 — Jyong Biotech announced updated Phase II clinical trial results for its investigational botanical drug MCS-8 (PCP), revealing statistically significant improvements in cholesterol and lactate dehydrogenase (LDH) biomarkers. The data reinforce MCS-8’s previously reported benefits in prostate cancer prevention while highlighting additional metabolic value, supporting its potential as a multi-indication preventive therapy.
Science Significance
The Phase II findings demonstrate that long-term treatment with MCS-8 resulted in a statistically significant reduction in total cholesterol levels, while avoiding the LDH elevation observed in placebo-treated subjects. LDH is widely used as a biomarker associated with cellular damage and disease progression, and its stability in the MCS-8 group suggests a favorable cellular safety profile. Importantly, previously disclosed efficacy data showed a 27.3% reduction in overall prostate cancer incidence and a 17.1% reduction in high-grade prostate cancer, along with improved pathological indicators of disease control. Collectively, the data suggest that MCS-8 may exert both oncologic and metabolic effects, supporting its scientific differentiation among plant-derived therapeutic candidates.
Regulatory Significance
From a cGxP perspective, the announcement reflects the successful conduct of a Phase II clinical trial under Good Clinical Practice (GCP) conditions, with validated endpoints and long-term safety follow-up. The absence of serious adverse events and lack of negative impact on liver, kidney, or cardiovascular function strengthen the regulatory foundation for continued development. The expanded biomarker dataset may support future regulatory discussions, including Phase III trial design and potential exploration of additional indications, while reinforcing confidence in the quality, consistency, and integrity of the clinical data package.
Business Significance
Advertisement
For Jyong Biotech, the results represent a strategic expansion of MCS-8’s commercial potential. Originally developed for prostate cancer prevention, the emerging metabolic data open opportunities in lipid management, atherosclerosis, and cardiovascular disease, significantly broadening the addressable market. This lifecycle extension strategy could enhance long-term asset value and support partnership, licensing, or regional commercialization opportunities. Positive Phase II data also strengthen the company’s positioning as a developer of evidence-based botanical pharmaceuticals, a growing segment within the global biopharma market
Patients’ Significance
For patients, particularly those at risk of prostate cancer or metabolic disorders, MCS-8 offers the promise of a well-tolerated, long-term preventive therapy. Two-year safety data indicate no increase in adverse events, supporting suitability for chronic administration. If validated in later-stage trials, MCS-8 could provide patients with a non-invasive option that addresses cancer risk while simultaneously supporting metabolic health, aligning with preventive medicine and early intervention strategies.
Policy Significance
The development of MCS-8 reflects broader policy interest in preventive healthcare, metabolic risk reduction, and innovation in botanical drug development. Regulators and health systems are increasingly focused on cost-effective, long-term interventions that reduce disease burden before progression to advanced stages. Demonstrating clinical efficacy and safety through rigorous trials supports the integration of plant-derived pharmaceuticals into mainstream regulatory and healthcare frameworks, potentially influencing future policy approaches to preventive therapies
With updated Phase II data reinforcing both cancer-preventive and metabolic benefits, Jyong Biotech continues to advance MCS-8 as a differentiated investigational therapy. While the drug remains unapproved, the results strengthen its scientific rationale, regulatory readiness, and commercial strategy, underscoring the role of GxP-aligned clinical development in translating botanical innovation into credible therapeutic options. Further studies will determine whether MCS-8 can progress toward broader clinical and regulatory milestones.
Source: Jyong Biotech Ltd. press release
